摘要
目的分析甲状腺功能亢进症(甲亢)继发骨质疏松患者应用瑞舒伐他汀联合阿仑膦酸钠治疗的临床效果,观察其对患者骨密度及血清游离三碘甲状腺原氨酸(FT_(3))、游离甲状腺素(FT_(4))、促甲状腺激素(TSH)、骨钙蛋白(BGP)的影响。方法60例甲亢继发骨质疏松患者,随机分为对照组和观察组,每组30例。对照组患者早餐前给予阿仑膦酸钠口服治疗,观察组给予瑞舒伐他汀联合阿仑膦酸钠治疗。比较两组患者治疗效果、骨折事件发生率以及治疗前后的骨密度、血清FT_(3)、FT_(4)、TSH、BGP水平。结果观察组治疗总有效率96.67%高于对照组的73.33%,差异具有统计学意义(χ^(2)=6.405,P=0.011<0.05)。治疗后,两组患者骨密度以及血清FT_(3)、FT_(4)、TSH、BGP水平均有所改善,且观察组改善程度大于对照组,差异均具有统计学意义(P<0.05)。观察组骨折事件发生率10.00%低于对照组的33.33%,差异具有统计学意义(χ^(2)=4.812,P=0.028<0.05)。结论甲亢继发骨质疏松患者采用瑞舒伐他汀和阿仑膦酸钠联合治疗效果确切,可提高骨密度,改善血清FT_(3)、FT_(4)、TSH、BGP指标,更好减少骨折事件发生率,具有临床推广意义。
Objective To analyze the clinical effect of rosuvastatin combined with alendronate sodium in the treatment of osteoporosis secondary to hyperthyroidism,and observe the influence on bone mineral density,serum free triiodothyronine(FT_(3))and free thyroxine(FT_(4)),thyroid stimulating hormone(TSH),bone gammacarboxyglutamic acid-containing protein(BGP).Methods A total of 60 patients with osteoporosis secondary to hyperthyroidism were randomly divided into the control group and the observation group,with 30 cases in each group.The control group was treated with oral administration of alendronate sodium before breakfast,and the observation group was treated with rosuvastatin and alendronate sodium.Both groups were compared in terms of therapeutic effect,incidence of fracture events,bone mineral density,serum FT_(3),FT_(4),TSH,and BGP before and after treatment.Results The total effective rate of treatment 96.67%in the observation group was higher than 73.33%in the control group,and the difference was statistically significant(χ^(2)=6.405,P=0.011<0.05).After treatment,the bone mineral density and serum FT_(3),FT_(4),TSH,and BGP of the two groups were improved,and the improvement in the observation group was greater than that of the control group.All the differences were statistically significant(P<0.05).The incidence of fracture events 10.00%in the observation group was lower than 33.33%in the control group,and the difference was statistically significant(χ^(2)=4.812,P=0.028<0.05).Conclusion Combination of rosuvastatin and alendronate sodium has definite effect on patients with osteoporosis secondary to hyperthyroidism,and it can improve the bone density,serum FT_(3),FT_(4),TSH,and BGP of patients,and reduce the incidence of fracture events,which contains clinical significance of promotion.
作者
王宁
WANG Ning(Endocrine Department,Shenyang Ninth People’s Hospital,Shenyang 110024,China)
出处
《中国现代药物应用》
2021年第21期159-162,共4页
Chinese Journal of Modern Drug Application
